Evidence map›Paper›PMID 35959109›Full record

ArticleJournal of clinical virology plus2022

Development and validation of an enzyme-linked immunoassay kit for diagnosis and surveillance of COVID-19.

Flávia F Bagno, Sarah A R Sérgio, Maria Marta Figueiredo, Lara C Godoi, Luis A F Andrade, Natália C Salazar, Camila P Soares, Andressa Aguiar, Flávia Jaqueline Almeida, Edimilson D da Silva and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical virology plus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Seroprevalence of SARS-CoV-2 in hospital workers in the southern region of Minas Gerais state in Brazil: An analysis of the pre-vaccine period.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Flávia F BagnoCentro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil.
Sarah A R SérgioCentro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil.
Maria Marta FigueiredoCentro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil.
Lara C GodoiCentro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil.
Luis A F AndradeCentro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil.
Natália C SalazarCentro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil.
Camila P SoaresUniversidade de São Paulo (USP), Instituto de Ciências Biomédicas, São Paulo, SP, Brazil.
Andressa AguiarGeriatric and Convalescent Hospital Dom Pedro II, São Paulo, SP, Brazil.
Flávia Jaqueline AlmeidaDepartment of Pediatrics, Santa Casa de São Paulo School of Medical Sciences, São Paulo, SP, Brazil.
Edimilson D da SilvaFundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
Antônio G P FerreiraFundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
Edison Luiz DurigonUniversidade de São Paulo (USP), Instituto de Ciências Biomédicas, São Paulo, SP, Brazil.
Ricardo T GazzinelliCentro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil.
Santuza M R TeixeiraCentro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil.
Ana Paula S M FernandesCentro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil.
Flavio G da FonsecaCentro de Tecnologia de Vacinas (CT Vacinas), BH-Tec, UFMG. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz · BRUniversidade Federal de Minas Gerais · BRUniversidade de São Paulo · BRColégio Pedro II · BRFaculdade de Ciências Médicas da Santa Casa de São Paulo · BRUniversidade do Estado de Minas Gerais · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a massive demand to identify alternative methods to detect new cases of COVID-19 as well as to investigate the epidemiology of the disease. In many countries, importation of commercial kits poses a significant impact on their testing capacity and increases the costs for the public health system. We have developed an ELISA to detect IgG antibodies against SARS-CoV-2 using a recombinant viral nucleocapsid (rN) protein expressed in

Indexed as

COVID-19DiagnosisELISAPrototypingSARS-CoV-2Serological assay

Identifiers

PMID35959109
PMCPMC9356643
OpenAlexW4291172090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.